{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:44:58Z","timestamp":1782758698815,"version":"3.54.5"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"DOI":"10.7759\/cureus.111747","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:00:11Z","timestamp":1782756011000},"source":"Crossref","is-referenced-by-count":0,"title":["Transthyretin Cardiac Amyloidosis in an Older Athlete"],"prefix":"10.7759","author":[{"given":"Daniel","family":"O'Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg FL","year":"2024","unstructured":"Ruberg FL, Maurer MS. Cardiac amyloidosis due to transthyretin protein: a review. JAMA. 2024, 331:778-91. 10.1001\/jama.2024.0442","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2024.10.011","article-title":"The last decade in cardiac amyloidosis: advances in understanding pathophysiology, diagnosis and quantification, prognosis, treatment strategies, and monitoring response","volume":"18","author":"Fontana M","year":"2025","unstructured":"Fontana M, Ioannou A, Cuddy S, et al.. The last decade in cardiac amyloidosis: advances in understanding pathophysiology, diagnosis and quantification, prognosis, treatment strategies, and monitoring response. JACC Cardiovasc Imaging. 2025, 18:478-99. 10.1016\/j.jcmg.2024.10.011","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer MS","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017, 135:1357-77. 10.1161\/CIRCULATIONAHA.116.024438","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.125.325638","article-title":"Athlete's heart revisited: historical, clinical, and molecular perspectives","volume":"137","author":"Hsieh PN","year":"2025","unstructured":"Hsieh PN, Shen S, Chukwurah MI, et al.. Athlete's heart revisited: historical, clinical, and molecular perspectives. Circ Res. 2025, 137:231-54. 10.1161\/CIRCRESAHA.125.325638","journal-title":"Circ Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12511","article-title":"Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis","volume":"6","author":"Brownrigg J","year":"2019","unstructured":"Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Fail. 2019, 6:1041-51. 10.1002\/ehf2.12511","journal-title":"ESC Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore JD","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al.. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024, 390:132-42. 10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana M","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, et al.. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025, 392:33-44. 10.1056\/NEJMoa2409134","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/492755-transthyretin-cardiac-amyloidosis-in-an-older-athlete","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:00:11Z","timestamp":1782756011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/492755-transthyretin-cardiac-amyloidosis-in-an-older-athlete"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.111747","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}